IL2 and hereditary clear cell renal cell carcinoma: Concurrent therapy with immune checkpoint inhibitor plus HD IL-2 has been explored in clinical trials for treatment of melanoma and renal cell carcinoma recently, based on reported synergy between IL-2 based therapy and checkpoint blockade in preclinical models (5).